Path: biomarkers/metabolomic-biomarkers-neurodegeneration
Metabolomics—the large-scale study of small-molecule metabolites in biological systems—offers a powerful window into the metabolic dysregulation that characterizes neurodegenerative diseases. Unlike genomics or proteomics, which reflect upstream molecular states, metabolomics captures the downstream functional consequences of disease processes, including alterations in energy metabolism, lipid homeostasis, neurotransmitter biosynthesis, and oxidative stress responses[1].
This page provides a comprehensive overview of metabolomic biomarkers for Alzheimer's disease, Parkinson's disease, ALS, and other neurodegenerative conditions, covering key metabolite classes, their disease relevance, analytical platforms, and clinical translation status.
Neurodegenerative diseases exhibit profound disruptions in cerebral energy metabolism, reflecting mitochondrial dysfunction, impaired glucose utilization, and altered substrate utilization[2].
Key Metabolites:
| Metabolite | Disease Association | Direction | Clinical Relevance |
|---|---|---|---|
| Lactate | AD, PD, ALS | ↑ | Marker of glycolytic shift and mitochondrial dysfunction |
| Pyruvate | AD, PD | ↓/↑ | Central carbon metabolism intermediate |
| Alpha-ketoglutarate | AD | ↓ | TCA cycle intermediate; reflects mitochondrial health |
| Succinate | AD, PD | ↑ | Indicator of complex II dysfunction |
| Citrate | AD | ↓ | TCA cycle metabolite; altered in early disease |
The increase in lactate-to-pyruvate ratio observed in neurodegenerative brains indicates a shift from efficient oxidative phosphorylation to aerobic glycolysis, a metabolic adaptation that accompanies mitochondrial compromise[3].
Amino acid neurotransmitters and their metabolic pathways are significantly altered in neurodegeneration, reflecting both neuronal loss and compensatory changes in neurotransmitter systems[4].
Glutamate and GABA:
Tryptophan and Kynurenine Pathway:
Branched-Chain Amino Acids (BCAAs):
Lipid homeostasis is severely disrupted in neurodegenerative diseases, with implications for membrane integrity, signaling, and inflammatory responses[6].
Sphingolipids:
Phospholipids:
Cholesterol and Sterols:
Purine and pyrimidine metabolism reflects cellular energy status and nucleic acid turnover in neurodegeneration[8].
Purines:
Pyrimidines:
The metabolomic signature of AD encompasses alterations in multiple metabolic pathways that reflect the characteristic pathological features of the disease[9].
Core Metabolomic Changes:
Diagnostic Potential:
PD metabolomics reveals characteristic alterations in energy metabolism, neurotransmitter metabolism, and lipid homeostasis[10].
Core Metabolomic Changes:
Progression Markers:
ALS metabolomics reflects the energetic crisis and metabolic dysregulation characteristic of motor neuron degeneration[11].
Core Metabolomic Changes:
Prognostic Potential:
Mass spectrometry remains the cornerstone of metabolomic analysis, offering high sensitivity and specificity for metabolite detection[12].
Gas Chromatography-Mass Spectrometry (GC-MS):
Liquid Chromatography-Mass Spectrometry (LC-MS):
Capillary Electrophoresis-Mass Spectrometry (CE-MS):
NMR-based metabolomics offers advantages in reproducibility and non-destructive analysis[13].
Advantages:
Limitations:
Metabolomic biomarker measurements are susceptible to preanalytical variability that must be carefully controlled[14].
Sample Collection:
Sample Handling:
Clinical translation of metabolomic biomarkers requires standardization across laboratories[15].
Current Initiatives:
Challenges:
Metabolomic profiling informs therapeutic development by identifying novel targets and enabling patient stratification[16].
Metabolic Targets:
Precision Medicine Applications:
The field of metabolomic biomarkers for neurodegeneration is evolving rapidly, with several key directions poised to advance clinical translation[17].
Emerging Technologies:
Integration Approaches:
Clinical Translation:
Kuehn B. Metabolomics Offers Insights into Neurodegeneration. JAMA. 2024. 2024. ↩︎
Cai H, et al. Metabolic alterations in Alzheimer's disease: current understanding and future perspectives. Nat Rev Neurol. 2023. 2023. ↩︎
Xu J, et al. Lactate metabolism in neurodegenerative diseases. Nat Rev Neurosci. 2024. 2024. ↩︎
Gupta M, et al. Amino acid metabolism in neurodegenerative diseases: implications for therapy. Nat Rev Drug Discov. 2023. 2023. ↩︎
Maddock J, et al. The kynurenine pathway in neurodegeneration: a meta-analysis. Mol Psychiatry. 2024. 2024. ↩︎
Chan RB, et al. Lipid alterations in neurodegenerative diseases: mechanisms and therapeutic implications. Nat Rev Neurol. 2023. 2023. ↩︎
Whiley L, et al. Lipidomic biomarkers for Alzheimer's disease: a systematic review and meta-analysis. Alzheimers Dement. 2024. 2024. ↩︎
Zhang W, et al. Nucleotide metabolism alterations in neurodegenerative diseases. Nat Rev Neurosci. 2024. 2024. ↩︎
Vanderstichele H, et al. [Metabolomics for Alzheimer's disease: moving towards clinical implementation. Lancet Neurol. 2023](https://doi.org/10.1016/S1474-4422(23). 2023. ↩︎
Fujita Y, et al. Metabolic signatures in Parkinson's disease: a systematic review. Mov Disord. 2024. 2024. ↩︎
Blasco H, et al. Metabolomics in ALS: current status and future directions. Ann Neurol. 2023. 2023. ↩︎
Dettmer K, et al. Mass spectrometry-based metabolomics: a practical introduction. Clin Chem. 2024. 2024. ↩︎
Emwas AH, et al. NMR-based metabolomics in human disease diagnosis: a review. Anal Chem. 2024. 2024. ↩︎
Kirpich IA, et al. Preanalytical considerations for metabolomics studies. Metabolomics. 2023. 2023. ↩︎
Zhou Y, et al. Standardization of metabolomics for clinical translation: a consensus statement. Nat Med. 2024. 2024. ↩︎
Minks E, et al. Metabolic targets for neurodegenerative disease therapy. Nat Rev Drug Discov. 2024. 2024. ↩︎
Kaddurah-Daouk R, et al. The future of metabolomics in neurological disorders. Nat Rev Neurol. 2025. 2025. ↩︎